





INTERNALLY FUNDED

EXTERNALLY FUNDED

| PRODUCT  | INDICATION/PHASE   | ANTIGEN                         | PARTNERS  |
|----------|--|---------------------------------|---|
| VGX-3100 | PRECANCEROUS CERVICAL DYSPLASIA (HSIL)<br><b>PHASE 3</b>   | HPV 16 E6, E7/<br>HPV 18 E6, E7 | <br><b>Apollobio</b><br><i>(China; INOVIO maintains global rights)</i> |
|          | PRECANCEROUS VULVAR DYSPLASIA (HSIL)<br><b>PHASE 2</b>   |                                 |   |
|          | PRECANCEROUS ANAL DYSPLASIA (HSIL)<br><b>PHASE 2</b>   |                                 |   |
| INO-3107 | RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP)<br><b>PHASE 2</b>                                     | HPV 6 E6, E7/<br>HPV 11 E6, E7  |   |
| MEDIO457 | HEAD & NECK CANCER<br><b>PHASE 2</b><br>CERVICAL, ANAL, PENILE, VULVAR CANCERS<br><b>PHASE 2</b> | HPV 16 E6, E7/<br>HPV 18 E6, E7 | AstraZeneca    |

**IMMUNO-ONCOLOGY (NON HPV-ASSOCIATED)**

|          |   |                  |  |
|----------|---|------------------|--|
| INO-5401 | GLIOBLASTOMA MULTIFORME (GBM)<br><b>PHASE 2</b> | WT1, PSMA, HTERT | <b>REGENERON</b>   |
| INO-5151 | PROSTATE CANCER<br><b>PHASE 2</b>               | PSA, PSMA        | <br>CANCER RESEARCH INSTITUTE<br><br>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY |

**INFECTIOUS DISEASES (NON HPV-ASSOCIATED)**

|                     |  |               |  |
|---------------------|--|---------------|--|
| PENNVAX-GP          | HIV<br><b>PHASE 2</b>                    | GAG, POL, ENV | <br>HIV VACCINE TRIALS NETWORK  |
| INO-4201            | EBOLA<br><b>COMPLETED PHASE 1</b>        | GLYCOPROTEIN  |   |
| INO-4700 (GLS-5300) | MERS<br><b>PHASE 2</b>                   | SPIKE         | <br><b>CEPI</b>   |
| INO-4600 (GLS-5700) | ZIKA<br><b>COMPLETED PHASE 1</b>         | GLYCOPROTEIN  |   |
| INO-4500            | LASSA FEVER<br><b>PHASE 1</b>            | GLYCOPROTEIN  | <b>CEPI</b>  |
| INO-4800            | COVID-19 (CORONAVIRUS)<br><b>PHASE 1</b> | SPIKE         | <br><b>CEPI</b><br><br>BILL & MELINDA GATES foundation |

**dMAb™ (DNA-ENCODED MONOCLONAL ANTIBODIES)**

|          |                        |              |                                 |
|----------|------------------------|--------------|---------------------------------|
| INO-A002 | ZIKA<br><b>PHASE 1</b> | GLYCOPROTEIN | BILL & MELINDA GATES foundation |
|----------|------------------------|--------------|---------------------------------|

| PRODUCT | INDICATION/PHASE | ANTIGEN | PARTNERS |
|---------|------------------|---------|----------|
|---------|------------------|---------|----------|

INTERNALLY FUNDED

EXTERNALLY FUNDED